---
title: "Relmada Therapeutics (RLMD.US) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RLMD.US/norm.md"
symbol: "RLMD.US"
name: "Relmada Therapeutics"
parent: "https://longbridge.com/en/quote/RLMD.US.md"
datetime: "2026-06-13T23:19:13.192Z"
locales:
  - [en](https://longbridge.com/en/quote/RLMD.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RLMD.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RLMD.US/norm.md)
---

# Relmada Therapeutics (RLMD.US) — Financial Reports

## Income Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| EPS | -0.2200 | -0.3252 | -0.3040 | -0.2973 | -0.5774 |
| ROE | -49.93% | -165.60% | -317.65% | -205.60% | -242.36% |
| Revenue | - | - | - | - | - |
| Net income | -19.05M | -19.87M | -10.09M | -9.87M | -17.56M |
| Operating income | -19.46M | -17.43M | -10.33M | -10.22M | -18.22M |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## Balance Sheet (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| A&L | 235.36M | 94.00M | 14.88M | 21.12M | 27.68M |
| Leverage | 1.08 | 1.09 | 1.57 | 1.32 | 1.23 |
| BVPS | 2.09 | 1.18 | 0.2852 | 0.4805 | 0.6761 |
| Turnover | - | - | - | - | - |
| Cash & STI | 233.96M | 93.01M | 13.89M | 20.62M | 27.06M |
| Inv & Rec | - | - | - | - | - |
| LT assets | - | - | - | - | - |
| Net debt | -233.96M | -93.01M | -13.89M | -20.62M | -27.06M |

## Cash Flow Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -15.07M | -14.60M | -6.72M | -6.40M | -18.07M |
| Investing CF | -135.23M | -76.93M | 6.75M | 6.68M | 15.36M |
| Financing CF | 156.57M | 93.64M | 0.0000 | -73021.00 | - |
| Free CF | -2.47M | -5.33M | -6.89M | -6.36M | -12.58M |
| OCF coverage | - | - | - | - | - |
| Repaid & issued | - | - | - | - | - |
| CapEx | - | - | - | - | - |